{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-200205","form_type":"8-K","ticker":"RAPP","cik":"0002012593","company_name":"Rapport Therapeutics, Inc.","filed_at":"2025-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.813716+00:00","generated_at":"2026-05-17T07:08:00.812854+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rapport Therapeutics announces $234.7M public offering of 9.6M shares at $26.00 per share","bullets":["Underwriting agreement for 9,615,385 shares at $26.00; underwriters option for up to 1,442,307 additional shares.","Net proceeds estimated at $234.7 million (excluding over-allotment).","Proceeds to fund RAP-219 clinical trials, R&D, and working capital.","Closing expected on or about September 11, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-200205","json":"https://secwatch.observer/filing/0001193125-25-200205.json","markdown":"https://secwatch.observer/filing/0001193125-25-200205.md","text":"https://secwatch.observer/filing/0001193125-25-200205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525200205/0001193125-25-200205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525200205/d907117d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:08:00.812854+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}